Vikram Purohit
Stock Analyst at Morgan Stanley
(0.87)
# 2,786
Out of 4,479 analysts
156
Total ratings
27.45%
Success rate
-23.97%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $136.27 | +2.74% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $78.93 | +45.70% | 17 | Apr 29, 2024 | |
| EXAI Exscientia | Maintains: Equal-Weight | $7 | $5.10 | +37.25% | 16 | Apr 22, 2024 | |
| ABVX Abivax | Maintains: Equal-Weight | $15 → $16 | $13.50 | +18.52% | 2 | Apr 11, 2024 | |
| CMPS COMPASS Pathways | Initiates: Overweight | $30 | $5.96 | +403.36% | 1 | Apr 1, 2024 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $20 → $22 | $10.82 | +103.33% | 6 | Feb 28, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $61 → $59 | $51.30 | +15.01% | 5 | Dec 26, 2023 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $19 → $13 | $4.12 | +215.53% | 6 | Nov 29, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $10 → $6 | $5.44 | +10.29% | 7 | Nov 13, 2023 | |
| VTYX Ventyx Biosciences | Downgrades: Equal-Weight | $46 → $6 | $2.14 | +180.37% | 1 | Nov 7, 2023 | |
| INCY Incyte | Maintains: Equal-Weight | $74 → $64 | $59.02 | +8.44% | 15 | Nov 1, 2023 | |
| RGNX REGENXBIO | Maintains: Overweight | $43 → $42 | $10.75 | +290.70% | 8 | Aug 29, 2023 | |
| EVLO Evelo Biosciences | Maintains: Equal-Weight | $2 → $10 | $0.04 | +24,900.00% | 4 | Jul 26, 2023 | |
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $7.16 | +53.63% | 1 | Jul 13, 2023 | |
| HOOK HOOKIPA Pharma | Maintains: Equal-Weight | $2 → $2.25 | $0.58 | +286.86% | 3 | Jun 5, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Overweight | $51 → $50 | $9.30 | +437.63% | 5 | Mar 1, 2023 | |
| AKLI Akili | Maintains: Equal-Weight | $2 → $3 | $0.43 | +594.44% | 2 | Jan 25, 2023 | |
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $38 → $41 | $30.22 | +35.67% | 9 | Dec 19, 2022 | |
| TIL Instil Bio | Maintains: Equal-Weight | $120 → $40 | $10.04 | +298.41% | 7 | Dec 12, 2022 | |
| PROK ProKidney | Initiates: Equal-Weight | $13 | $2.24 | +480.36% | 1 | Nov 10, 2022 | |
| SDGR Schrödinger | Maintains: Equal-Weight | $39 → $38 | $20.33 | +86.92% | 5 | Nov 4, 2022 | |
| CERT Certara | Maintains: Equal-Weight | $24 → $20 | $13.66 | +46.41% | 4 | Aug 24, 2022 | |
| TBPH Theravance Biopharma | Maintains: Underweight | $11 → $10 | $8.32 | +20.19% | 7 | Jul 25, 2022 | |
| RDUS Radius Health | Downgrades: Underweight | n/a | $14.67 | - | 3 | Dec 10, 2021 | |
| TCRX TScan Therapeutics | Initiates: Overweight | n/a | $5.73 | - | 1 | Aug 10, 2021 | |
| DBVT DBV Technologies | Maintains: Equal-Weight | $8 → $4 | $0.77 | +418.20% | 2 | Aug 5, 2020 |
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $136.27
Upside: +2.74%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $78.93
Upside: +45.70%
Exscientia
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $7
Current: $5.10
Upside: +37.25%
Abivax
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $13.50
Upside: +18.52%
COMPASS Pathways
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $5.96
Upside: +403.36%
Sage Therapeutics
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $10.82
Upside: +103.33%
Halozyme Therapeutics
Dec 26, 2023
Maintains: Overweight
Price Target: $61 → $59
Current: $51.30
Upside: +15.01%
Acelyrin
Nov 29, 2023
Maintains: Equal-Weight
Price Target: $19 → $13
Current: $4.12
Upside: +215.53%
Foghorn Therapeutics
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $10 → $6
Current: $5.44
Upside: +10.29%
Ventyx Biosciences
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.14
Upside: +180.37%
Incyte
Nov 1, 2023
Maintains: Equal-Weight
Price Target: $74 → $64
Current: $59.02
Upside: +8.44%
REGENXBIO
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $10.75
Upside: +290.70%
Evelo Biosciences
Jul 26, 2023
Maintains: Equal-Weight
Price Target: $2 → $10
Current: $0.04
Upside: +24,900.00%
Recursion Pharmaceuticals
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $7.16
Upside: +53.63%
HOOKIPA Pharma
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $2 → $2.25
Current: $0.58
Upside: +286.86%
Arcutis Biotherapeutics
Mar 1, 2023
Maintains: Overweight
Price Target: $51 → $50
Current: $9.30
Upside: +437.63%
Akili
Jan 25, 2023
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $0.43
Upside: +594.44%
Kymera Therapeutics
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $30.22
Upside: +35.67%
Instil Bio
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $10.04
Upside: +298.41%
ProKidney
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.24
Upside: +480.36%
Schrödinger
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $20.33
Upside: +86.92%
Certara
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $13.66
Upside: +46.41%
Theravance Biopharma
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $8.32
Upside: +20.19%
Radius Health
Dec 10, 2021
Downgrades: Underweight
Price Target: n/a
Current: $14.67
Upside: -
TScan Therapeutics
Aug 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $5.73
Upside: -
DBV Technologies
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $0.77
Upside: +418.20%